
Shengfang Jin, Ph.D.
President and CEO, Board of Director
Shengfang is a co-founder, President and CEO, and Board of Director of Ensem Therapeutics. Prior to her role as CEO, she served as the President and Chief Scientific Officer, driving ENSEM’s strategic initiatives, technology platforms, and R&D. Previously, she was Vice President of Discovery Biology at Editas Medicine (EDIT), a clinical-stage gene editing company. Her teams pioneered the discovery of advanced CRISPR gene and cell therapies focusing on ophthalmology, neural diseases, and oncology. Earlier in her career, Dr. Jin was Senior Director of Biology at Agios Pharmaceuticals, leading the Small Molecule Cancer Metabolism and Rare Genetic Disease Portfolios that culminated in the approved & first-in-class products (IDHIFA®, TIBSOVO®, PYRUKYND®) and other clinical stage programs. She has also held roles of increasing responsibilities in other Cambridge drug discovery companies. Shengfang is a passionate & enthusiastic motivator, empowering team members to lead and shine.
Shengfang is co-author/co-inventor of over 80 peer-reviewed publications and issued patents. She holds a Ph.D. in Molecular Biology and Microbiology from Tufts Medical School (Boston) and obtained postdoctoral training in Oncology and Tumor Immunology at Harvard Medical School (Boston) as an NIH Fellow.

Ron Peck, M.D.
Chief Medical Officer
Ron Peck, M.D. is a medical oncologist and biopharmaceutical leader with 30 years of expertise in oncology drug development. He is founder and principal consultant of Veritas Oncology LLC.
Prior to founding Veritas, Dr. Peck served as Chief Medical Officer at Arvinas during a period of rapid growth in the company’s development activities. He oversaw the advancement of the estrogen receptor degrader vepdegestrant into multiple Phase 3 trials in partnership with Pfizer, the development of two androgen receptor degraders through proof of concept, which led to the licensing of ARV-766 to Novartis, and the initiation of first-in-human studies with two other novel first-in-class PROTAC agents.
Prior to Arvinas, Dr. Peck was SVP, Head of Clinical Research at TESARO Inc. (acquired by GSK) and CMO at Kolltan Pharmaceuticals. Before Kolltan, Dr. Peck spent 15 years at Bristol Myers Squibb in roles of increasing responsibility in clinical research and product development, contributing to the development of drugs such as ipilimumab, ixabepilone, and dasatinib.
Dr. Peck is an adjunct assistant professor in hematology/oncology at Yale University. He earned his M.D. from Thomas Jefferson University and completed his internal medicine residency and fellowship in oncology and hematology at Georgetown University, where he also completed a fellowship in developmental therapeutics.

Lori Cykowski, MS
Vice President, Clinical Operations
Lori leads Clinical Operations at ENSEM Therapeutics, overseeing the execution of global clinical trials and enabling the efficient advancement of the company’s pipeline. She brings over 30 years of experience in pharmaceutical and medical device clinical research, with deep expertise in oncology and immuno-oncology.
Prior to joining Ensem, she held roles of increasing responsibility at Bristol-Myers-Squibb, EMD Serono, and most recently Arvinas. She brings deep expertise in leading teams across all phases of development (I–IV) and in shaping and executing clinical operations strategies.
Lori holds an M.S. in Biotechnology from the University of Connecticut and a B.S. in Biology from Elms College.

Géralyn C. Trudel, Ph.D.
Clinical Lead/Development Advisor
Géralyn is a senior clinical development leader with more than 35 years of international experience in Phase 1–3 drug development. She has contributed to more than 20 successful IND and NDA submissions in oncology/hematology, neurology and infectious disease. At Ensem, she serves as Clinical Lead, bringing deep expertise in clinical science and medical monitoring to the company’s clinical programs. Since 2021, she has been an independent consultant in clinical research and development. Her consulting work covers mRNA platforms, vaccines and anti-infectives, bispecific antibodies for oncology, and ASCO’s initiative to standardize oncology trial endpoints.
Before consulting, Géralyn spent most of her career in global oncology/hematology R&D. At Johnson & Johnson (Janssen) she served in a leadership position to oversee the scientific integrity of a portfolio that included four Phase 3 prostate cancer trials and hematology combination studies contributed to the approval of indications for apalutamide (Erleada®). Earlier at Janssen, she oversaw more than 100 investigator-initiated studies for VELCADE®. As a Director at Bristol-Myers Squibb, she provided medical and scientific oversight of Phase 1–4 trials in the immuno-oncology portfolio. She started her career at Berlex Canada, where she helped develop Betaseron®, the first treatment for multiple sclerosis.
Géralyn received her Ph.D. from McGill University’s Department of Neurology and Neurosurgery and did a postdoctoral fellowship in neuro-immunology at McGill, funded by the MS Society of Canada.

Lancy (Yan) Zhou
Director, China Clinical Operations
Lancy leads China Clinical Operations at Ensem Therapeutics, bringing nearly 16 years of industry experience across top-tier multinational pharmaceutical companies, global CROs, and biotech innovators, including Merck, IQVIA, Eli Lilly, Bayer, GSK, and Regor.
Prior to joining ENSEM, Lancy was Director of Clinical Operations at Regor Pharmaceuticals, overseeing delivery of the company’s Phase I and II oncology and metabolic disease studies in China and the US, including CRO and vendor management, site relationships, and regulatory submission strategy (HGRAC). She previously held roles of increasing responsibility at Merck, IQVIA, and Eli Lilly, managing site relationships, CRO oversight, and study execution for global development programs in China, and began her career as a Clinical Research Associate at Bayer and GSK.
Lancy brings over twelve years of combined project management and people management expertise, with a therapeutic focus spanning oncology, respiratory, metabolism, cardiovascular disease, and gynecology. She holds a Bachelor’s degree in Clinical Medicine from Hebei Medical University, China.

Raj Nagaraja, Ph.D.
Senior Vice President & Head of DMPK & Program Management
Raj comes from Servier Pharmaceuticals where he worked as the Senior Director and Head of DMPK (US). He has over 20 years of experience in the field of DMPK at top pharma companies (Servier, Agios Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Millennium Pharmaceuticals/Takeda, and DuPont/Bristol Myers Squibb). He has experience in both small and large molecules DMPK in exploratory research, lead optimization, IND filing, and in various capacities in clinical trial phases. Raj has successfully incorporated the translational biomarkers in several drug discovery and development programs. His research interests are Discovery and Development DMPK, Clinical Pharmacology, and PKPD modeling and simulations. Raj has co-authored/co-invented more than 30 peer-reviewed publications and patents.
Raj obtained his B.S. and M.S. in Pharmacy, a Ph.D. in Pharmacokinetics and Drug Metabolism from Central Drug Research Institute, India, and did Postdoctoral research at University of Florida.

Eric Simone, Ph.D.
Vice President and Head of Technical Operations
Eric brings extensive industry experience working at the interface of development with research, clinical and commercial development in Oncology, Antivirals and Rare Genetic Diseases. Prior to joining Ensem Therapeutics, Eric was the Senior Director of Formulation Development and Manufacturing at Agios Pharmaceuticals. Eric and his team focused on novel platforms and rapidly enabling formulations for poor solubility and low permeability therapeutics for multiple oncology and hemolytic anemia programs. Before Agios, Eric worked at Vertex Pharmaceuticals focusing on small molecules for HCV, influenza and Cystic Fibrosis, along with building out their continuous manufacturing initiative. In addition to leading several CMC Tech Teams, Eric was a central part of a virtual “FluDev” team, running all CMC and supply chain aspects of a Ph2b clinical study spanning seven countries and over 200 clinical sites.
Eric trained at Johns Hopkins University and the University of Pennsylvania for his B.S. and Ph.D. respectively in biomedical engineering. He was a post-doctoral fellow in Radiology at the Hospital of the University of Pennsylvania.
Board of Directors

Shengfang Jin, Ph.D.
President and CEO, Board of Director
Shengfang is a co-founder, President and CEO, and Board of Director of Ensem Therapeutics. Prior to her role as CEO, she served as the President and Chief Scientific Officer, driving ENSEM’s strategic initiatives, technology platforms, and R&D. Previously, she was Vice President of Discovery Biology at Editas Medicine (EDIT), a clinical-stage gene editing company. Her teams pioneered the discovery of advanced CRISPR gene and cell therapies focusing on ophthalmology, neural diseases, and oncology. Earlier in her career, Dr. Jin was Senior Director of Biology at Agios Pharmaceuticals, leading the Small Molecule Cancer Metabolism and Rare Genetic Disease Portfolios that culminated in the approved & first-in-class products (IDHIFA®, TIBSOVO®, PYRUKYND®) and other clinical stage programs. She has also held roles of increasing responsibilities in other Cambridge drug discovery companies. Shengfang is a passionate & enthusiastic motivator, empowering team members to lead and shine.
Shengfang is co-author/co-inventor of over 80 peer-reviewed publications and issued patents. She holds a Ph.D. in Molecular Biology and Microbiology from Tufts Medical School (Boston) and obtained postdoctoral training in Oncology and Tumor Immunology at Harvard Medical School (Boston) as an NIH Fellow.

Neo Zhang
Board of Director, CBC Managing Director
Mr. Zhang has been with CBC since its founding, in January 2014, and most recently serving as a Managing Director and was responsible for the fund’s investments in pharmaceutical and biotech industry. During 2019-2023, he was an executive Director, Chief Operating Officer of Everest Medicines, a HK publicly listed biopharmaceutical company incubated by CBC. Prior to joining CBC Group, Mr. Zhang worked in various capacities in private equity and investment banking, including as a private equity investment officer at Capital International, Inc., a private equity arm of Capital Group, from March 2011 to February 2013, at Morgan Stanley Asia Limited, a subsidiary of Morgan Stanley (NYSE: MS), from May 2007 to March 2011 where his last position held was associate, and at BOCI Research Limited and BOCI Securities Limited from 2006 to 2007. Mr. Zhang received his bachelor’s degree in mathematics with honors from The University of Hong Kong in December 2006.

Sean Cao, Ph.D., MBA
Board of Director, ABio-X CEO
Prior to joining ABio-X, Sean was a Managing Director of CBC Group, co-founded and served as the CEO of Everest Medicines and was the VP of Global Business Development at Simcere Pharmaceutical Group. Sean was also the President and Board Director at Simcere America, a wholly owned subsidiary. Previously, Sean was the Senior Director of Alternative Partnerships, Evaluation & Expertise at Sanofi. Before Sanofi, Sean was an Associate at New Leaf Venture Partners, a healthcare VC firm. Earlier in his career, Sean worked in the pharmaceutical and diagnostic industries at Aventis and Johnson & Johnson. Sean currently serves as the Chairman of NiKang Therapeutics. He holds a PhD in Microbiology from the University of Virginia, an MBA with honor from the Wharton School of the University of Pennsylvania, and a Bachelor of Science in Microbiology from Nankai University, China.

Joshua Wu
Board of Director, GGV Partner
Joshua Wu has served on ENSEM’s Board since April 2022. He is a Partner at GGV Capital, focusing on investments in a variety of sectors.
Joshua began his career at Alibaba, where he was a product manager in Yahoo! Chinese search analysis and the data solutions team. After Alibaba, he joined Tencent, where he served as an Associate Director of the portal and media sales group, overseeing the data analysis and strategy efforts of the media sales business. Joshua began his career with Jefferies & Company, one of the world’s largest full-service investment banks, where he was an equity analyst for Asia TMT and participated in Renren’s IPO on NASDAQ, one of China’s largest tech IPOs at the time. Joshua is a graduate of Peking University Guanghua School of Management.
https://www.ggvc.com/team/joshua-wu/
Distinguished Advisors

Shin-San Michael Su, Ph.D.
Scientific Advisor
Dr. Su is a pioneering biotech leader with deep expertise in drug discovery and translational medicine. He served as Chief Scientific Officer of Volastra Therapeutics and as Chief Scientific Officer of Decibel Therapeutics. Before that, Dr. Su was a Co-founder and Senior Vice President of Research and Development at Agios Pharmaceuticals, where he led the team responsible for identifying the oncogenic cause of IDH mutants in cancer and the discovery of IDHIFA® and TIBSOVO®, FDA-approved treatments for AML with IDH mutations. He served as General Director and Vice President of the Biomedical Engineering Research Laboratory at ITRI in Taiwan and spent 14 years in scientific leadership roles at Vertex Pharmaceuticals, concluding his tenure as Program Executive and Vice President of the Novartis-Vertex kinase collaboration.
Dr. Su has a Ph.D. in biochemistry from Duke University and completed postdoctoral work through the Helen Hay Whitney Foundation Fellowship in biochemistry and molecular biology at Harvard University.

Jeff Kutok, M.D., Ph.D.
Senior Advisor
Jeff is a physician and scientist and serves as a Senior Advisor (CSO from January 2024 to October 2026) to ENSEM Therapeutics. He comes to ENSEM with more than 25 years clinical practice, translational scientific research, and biotech leadership experience in oncology, immuno-oncology, and epigenetics. As an experienced biotech executive in the drug development space, Jeff recently served as the Chief Scientific Officer at Epizyme, Inc., where he led the company’s scientific strategy, including directing preclinical research to support the further development of the EZH2 inhibitor, TAZVERIK® (tazemetostat), and advancing the company’s broader epigenetic pipeline. He also served as a member of the leadership team during its acquisition by Ipsen. Prior to joining Epizyme, he served as Executive Vice President and Chief Scientific Officer at Infinity Pharmaceuticals, Inc. where he was responsible for the company’s scientific strategy, preclinical development, and translational science. During his tenure at Infinity, the company advanced several oral PI3K inhibitors into the clinic. He was also part of the leadership team during the AbbVie partnership and was involved in the licensing of the PI3Kδ/ɣ inhibitor, COPIKTRA® (duvelisib) to Verastem Oncology.
Prior to his industry experience, Jeff was an Associate Professor of Pathology at Harvard Medical School and Brigham and Women’s Hospital (BWH) and is board certified in Anatomic Pathology and Hematology. His laboratory at BWH focused on translational medicine research and biomarker identification in oncology and he is a leading expert in cancer biology, with authorship on over 200 journal articles, reviews, and book chapters. Jeff received his B.S. in Biology and his M.D., Ph.D. in Medicine and Molecular Pathology from Stony Brook University.

Duncan Higgons
Business Advisor
Duncan has held multiple senior operating positions in biotech over the past 20 years and has served on multiple boards. Duncan was the Chief Operating Officer of Agios Pharmaceuticals from 2009 to 2016. He served as Executive Vice-President, Interim President and Chief Executive Officer at Archemix Corporation from 2006 to 2009. Prior to Archemix, Duncan was the Chief Commercial Officer at TransForm Pharmaceuticals, Inc., a privately-held biotechnology company which was acquired by Johnson & Johnson Company. He has served on the boards of Jounce, Rheos, and Auron, and was Chairman of the Board of Akamis for 7 years. He holds a B.Sc. in Mathematics from King’s College University of London and an M.Sc. in Economics from London Business School.

Tao Liu, Ph.D.
Medicinal Chemistry Advisor
Tao brings over 19 years of experience in leading the discovery and development of innovative drug candidates in Oncology and Rare Genetic Disease area. Prior to joining Ensem Therapeutics, Tao was the Director of Medicinal Chemistry at Agios Pharmaceuticals, where he was project leader for multiple programs, and led the discovery of AG-946 as the next generation of PKR activator, currently in Phase I clinical trial. Before that, Tao held positions of increasing responsibilities in medicinal chemistry group at Infinity Pharmaceuticals, where he was an intellectual leader for the discovery of PI3K-gamma selective drug candidate IPI-549 (Eganelisib), which is in Phase II clinical development in oncology.
Tao earned a B.S. in chemistry from University of Science and Technology of China, and a Ph.D. in Organic Chemistry from Brandeis University, and completed a Postdoctoral Fellow in Chemistry at Boston College.

Ming-Hong Hao, Ph.D.
AI/ML Computational Chemistry Advisor
Ming-Hong is responsible for creating and implementing Ensem Therapeutic’s core technologies on simulating protein/RNA structural dynamics and conformational ensemble and translating these insights into innovative therapeutics. He will guide the team to integrate proprietary experimental protein structural and dynamic data into predictive theoretical models; unleash the combined power of sophisticated peptide sampling methods, advance AI-based protein 3D structure and ligand-binding pocket recognition algorithms and multi-level molecular dynamics simulations.
Ming-Hong is a highly successful and well-recognized computational chemist with 23 years of experience in drug discovery in the pharmaceutical industry. He has made key contributions based on computational approaches to create four clinical drug candidates in Oncology. Before Joining Ensem Therapeutics, he worked at Boehringer Ingelheim, H3 Biomedicine, Eisai and Agios with increasing responsibilities. Ming-Hong received a Ph.D. from Rutgers University and did postdoctoral research at Cornell University, where he built deep and broad expertise in structural biology and MM/QM computational sciences. He has authored/co-authored more than 50 peer-reviewed scientific papers. He is also co-inventor of 20 issued patents.
